Healthcare > Pharmaceuticals & Biotechnology
•2432 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2432)
| Company | Market Cap | Price |
|---|---|---|
|
GMAB
Genmab A/S
Genmab is a biotechnology company focused on oncology therapeutics, fitting Biotech - Oncology.
|
$20.69B |
$32.26
-4.70%
|
|
PODD
Insulet Corporation
The insulin delivery platform functions as a drug delivery platform enabled by a medical device.
|
$20.25B |
$287.73
+0.43%
|
|
BWXT
BWX Technologies, Inc.
Radiopharmaceuticals for nuclear medicine imaging and diagnostics.
|
$19.91B |
$217.84
+2.15%
|
|
EXAS
Exact Sciences Corporation
Oncotype DX is a genomic assay used as a companion diagnostic in oncology, and the company discusses companion diagnostic capabilities and leadership in Precision Oncology.
|
$19.39B |
$102.46
+0.12%
|
|
WST
West Pharmaceutical Services, Inc.
West generates revenue from contract manufacturing services, moving towards higher-margin opportunities.
|
$18.68B |
$259.81
-7.01%
|
|
IFF
International Flavors & Fragrances Inc.
DEB and enzyme-based biotechnologies are core to IFF's Health & Biosciences innovation and product offerings.
|
$18.37B |
$71.71
+1.24%
|
|
MEDP
Medpace Holdings, Inc.
Medpace's core business is a specialized full-service CRO delivering Phase I–IV clinical development services.
|
$17.16B |
$610.38
-1.24%
|
|
MRNA
Moderna, Inc.
Direct vaccines products (Spikevax and pipeline vaccines) are Moderna's core revenue drivers and product line.
|
$16.28B |
$41.83
+6.28%
|
|
ROIV
Roivant Sciences Ltd.
Immunovant's FcRn-targeting therapies (e.g., IMVT-1402, batoclimab) are monoclonal antibody therapeutics.
|
$15.80B |
$23.11
-0.79%
|
|
VTRS
Viatris Inc.
Viatris is a large-scale producer of generic medicines and biosimilars, core to its business.
|
$14.99B |
$12.86
+0.12%
|
|
BBIO
BridgeBio Pharma, Inc.
BBP-812 is an AAV9 gene therapy candidate for Canavan disease, a gene therapy product.
|
$14.58B |
$76.26
|
|
ICLR
ICON Public Limited Company
Directly describes ICON's outsourced drug development and management services as a Contract Research Organization.
|
$14.20B |
$182.94
+0.21%
|
|
OKLO
Oklo Inc.
Atomic Alchemy's production of high-value radioisotopes for medical, industrial, defense, and AI applications aligns with radiopharmaceuticals.
|
$14.02B |
$94.92
+3.79%
|
|
GH
Guardant Health, Inc.
Companion diagnostics: Guardant's tests serve as companion diagnostics for cancer therapies.
|
$13.98B |
$112.17
+0.17%
|
|
RGC
Regencell Bioscience Holdings Limited
Regencell Bioscience focuses on neuropsychiatric drug development for ADHD/ASD, aligning with Neuropsychiatric Drug Development.
|
$13.56B |
$27.76
-7.65%
|
|
NBIX
Neurocrine Biosciences, Inc.
Neurocrine's core focus is neuroscience with programs in neuropsychiatric disorders (MDD, schizophrenia, TD) and related CNS conditions.
|
$13.13B |
$132.38
-0.73%
|
|
SMMT
Summit Therapeutics Inc.
Ivonescimab is a PD-1/VEGF bispecific antibody, placing Summit in the Bispecific Antibodies investable theme.
|
$12.66B |
$17.04
-1.36%
|
|
ASND
Ascendis Pharma A/S
Ascendis Pharma focuses on rare-disease endocrinology therapies (YORVIPATH, SKYTROFA, TransCon CNP) within biotech, fitting the Biotech - Rare Diseases category.
|
$12.46B |
$205.98
-4.21%
|
|
ELAN
Elanco Animal Health Incorporated
Vaccines are a major product category and a focus of Elanco's innovation pipeline.
|
$12.19B |
$24.54
+1.47%
|
|
IONS
Ionis Pharmaceuticals, Inc.
Ionis's core platform is RNA-targeted antisense oligonucleotides, directly aligning with the Oligonucleotide Therapeutics category.
|
$12.17B |
$76.29
-1.19%
|
|
EXEL
Exelixis, Inc.
Exelixis is a biotech company focused on oncology therapies, including cabozantinib (CABOMETYX) and pipeline assets.
|
$11.83B |
$43.99
-3.19%
|
|
MDGL
Madrigal Pharmaceuticals, Inc.
Rezdiffra is an oral, small-molecule therapeutic (THR-β agonist) approved for MASH, directly matching the 'Oral Small Molecule Therapeutics' category.
|
$11.18B |
$501.63
+1.16%
|
|
CRL
Charles River Laboratories International, Inc.
CRL operates as a contract research organization, outsourcing preclinical drug development services.
|
$10.81B |
$219.73
-1.67%
|
|
RDY
Dr. Reddy's Laboratories Limited
Significant emphasis on biosimilar development and commercialization.
|
$10.76B |
$12.91
-1.34%
|
|
TECH
Bio-Techne Corporation
Bio-Techne's core business includes recombinant proteins and enzymes used as highly characterized reagents across life-science workflows.
|
$10.68B |
$68.67
-1.84%
|
|
BMRN
BioMarin Pharmaceutical Inc.
BioMarin's core commercial therapies (VOXZOGO for skeletal disorders and enzyme replacement therapies like PALYNZIQ, VIMIZIM, NAGLAZYME) are all in the rare diseases space, fitting the Biotech - Rare Diseases investable theme.
|
$10.48B |
$54.62
-0.82%
|
|
QGEN
Qiagen N.V.
QIAstat-Dx serves as companion diagnostics in pharma collaborations, aligning with the Companion Diagnostics tag.
|
$10.36B |
$47.58
-1.66%
|
|
BAX
Baxter International Inc.
Pharmaceuticals segment aligns with Large Cap Pharma as Baxter pursues new product launches.
|
$10.33B |
$20.12
-1.23%
|
|
JAZZ
Jazz Pharmaceuticals plc
Zanidatamab is a bispecific antibody, a core oncology modality represented by Bispecific Antibodies.
|
$10.28B |
$169.37
-1.05%
|
|
RNA
Avidity Biosciences, Inc.
Direct product modality: oligonucleotide therapeutics (AOC platform) delivering RNA payloads.
|
$9.33B |
$72.50
-0.13%
|
|
VRNA
Verona Pharma plc
Verona's Ohtuvayre (ensifentrine) is a small-molecule therapeutic used for COPD management.
|
$9.10B |
$106.91
|
|
AXSM
Axsome Therapeutics, Inc.
Axsome's revenue drivers Auvelity and Sunosi and pipeline products are oral small-molecule therapeutics.
|
$8.85B |
$177.27
+1.80%
|
|
ARWR
Arrowhead Pharmaceuticals, Inc.
Arrowhead's core platform and lead programs are based on RNA interference (siRNA) therapeutics, i.e., RNAi Therapeutics.
|
$8.83B |
$63.85
-3.62%
|
Showing page 3 of 25 (2432 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
